US2003166517A1PendingUtilityA1

Galenical formulations

Priority: May 27, 1993Filed: Mar 12, 2003Published: Sep 4, 2003
Est. expiryMay 27, 2013(expired)· nominal 20-yr term from priority
A61K 9/1075A61K 31/70A61P 37/06A61P 37/00A61K 9/4858A61K 47/10A61K 31/436A61K 47/44A61P 37/02
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition containing macrolide, e.g. a rapamycin compound in an emulsion preconcentrate or microemulsion preconcentrate for oral administration. The carrier medium for the rapamycin compound includes a hydrophilic phase, a lipophilic phase and a surfactant. The composition is stable and provides high absorption efficiency.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a macrolide and a carrier medium comprising a hydrophilic phase, a lipophilic phase and a surfactant.  
     
     
         2 . A composition according to  claim 1  in the form of an emulsion or a microemulsion preconcentrate.  
     
     
         3 . A composition according to  claim 1  or  claim 2  in which the lipophilic phase comprises 10 to 85% by weight of the carrier medium.  
     
     
         4 . A composition according to any one of  claims 1  to  3  in which the surfactant comprises 5 to 80% by weight of the carrier medium.  
     
     
         5 . A composition according to any one of  claims 1  to  4  in which the hydrophilic phase comprises 10 to 50% by weight of the carrier medium.  
     
     
         6 . A composition according to any one of  claims 1  to  5  in which the compound of the rapamycin class is present in an amount of 2 to 15% by weight of the composition.  
     
     
         7 . A composition according to any one of  claims 1  to  6  in which the macrolide is a compound of the rapamycin class.  
     
     
         8 . A composition according to any one of  claims 1  to  6  in which the macrolide is a FK 506 compound.  
     
     
         9 . An microemulsion preconcentrate carrier medium for an orally administrable active agent other than a cyclosporin which comprises 
 i) a reaction product of a castor oil and ethylene oxide,    ii) a transesterification product of a vegetable oil and glycerol comprising predominantly linoleic acid or oleic acid, mono-, di- and triglycerides or a polyoxyalkylated vegetable oil,    iii) 1,2 propylene glycol and    iv) ethanol.

Join the waitlist — get patent alerts

Track US2003166517A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.